产品获批的那一天，很多公司会庆祝。开香槟、发邮件、启动市场推广。然后所有人的注意力都转向销售和扩张。

但做过几年法规的人都清楚—获批不是终点，而是持续合规的起点。 那些在庆祝之后放松警惕的公司，后面往往要付出更高的代价。

以下是产品获批后，不同产品类型最常遇到的“持续性工作”：

1. 安全信息一直在变

对药品来说，上市后的药物警戒活动会持续很多年。安全团队不断更新安全性数据，最终反映到标签变更、警告信息更新、说明书修订。总部把变更方案发给各国法规团队，各地再准备变更申请、更新包装、协调新旧库存的过渡。没有提前规划，新旧标签共存就成了商业和法规团队之间的拉锯战。

2. 生产端从来不消停

供应商变更、CEP更新、工艺优化、年检……每一项都可能触发法规变更。医疗器械也一样，工艺更新、供应商换人、零部件修改、软件升级，都得在实施前评估是否需要提交变更。

3. 商业需求也在制造法规工作

市场部永远在想办法让产品更有竞争力。扩大宣称、换包装、推新配方、增加产品线——这在保健品和化妆品行业尤其常见。一个看似简单的市场决策，背后可能就是配方审核、标签评估、产品再通报或全新的注册申请。

4. 供应链一直在变

现在全球供应链变化越来越频繁。引入第二生产基地、委外生产、换原料供应商、外包包装——这些都是为了降本增效，但每一项都可能需要法规评估和批准。

真正的问题：内部团队忙不过来

在很多公司，上市后的法规工作要和日常商业优先级抢资源。内部团队既要支持新品上市，又要维护现有证照、回复总部、准备变更、审核包装、回答经销商问题、跟踪法规变化……同时还得确保产品不断供。

结果就是：提交延迟、新旧包装共存、市场上市延期、内部扯皮增多。这些问题，往往不是团队能力不够，而是法规生命周期管理缺乏持续规划。

TRC能做什么

我们不是等到出问题才介入。我们的订阅计划，专为那些需要持续法规支持的公司设计——帮你在产品生命周期的每个阶段提前规划、协调实施、维持合规。

产品获批只是开始。真正走得远的公司，是那些获批之后，依然有清晰法规规划的企业。

如果你需要一个能帮你管理上市后合规工作的新加坡本地伙伴，欢迎联系我们。

Many companies celebrate once their product receives regulatory approval. Marketing campaigns begin, commercial supply is launched, and attention quickly shifts towards sales and business expansion.

However, experienced regulatory professionals know that product approval is not the finish line. In reality, it marks the beginning of a continuous regulatory lifecycle.

Throughout the years following approval, products continue to evolve. Manufacturing processes improve, safety information is updated, suppliers change, formulations are refined, labels are revised, and regulatory expectations continue to develop. Companies that fail to plan for these post-approval obligations often discover that maintaining compliance requires considerably more effort and resources than obtaining the original approval itself.

1. Safety Information Never Stops Evolving

For pharmaceutical products, pharmacovigilance activities continue long after approval. Safety teams constantly monitor, evaluate and characterise emerging safety signals to ensure that products continue to demonstrate a favourable benefit-risk profile.

Periodic Safety Update Reports (PSURs), together with updates to the Company Core Safety Data Sheet (CCDS), frequently result in changes to product labelling, warnings, precautions or prescribing information. Headquarters then coordinate these updates globally, requiring local regulatory teams to prepare variation applications, implement revised artwork and carefully manage the commercial transition between existing and updated packaging.

Without proper planning, companies often struggle with overlapping inventories, inconsistent implementation timelines and increasing pressure from both commercial and regulatory teams.

2. Manufacturing Improvements Create Continuous Regulatory Work

Manufacturing excellence is never static.

Supplier qualification, Certificate of Suitability (CEP) updates, pharmacopoeial revisions, process optimisation and Annual Product Reviews continuously drive improvements in pharmaceutical manufacturing.

In addition, inspection findings from health authorities or third-party audits frequently require process enhancements, revised specifications or manufacturing changes before implementation.

While these improvements strengthen product quality and supply reliability, they often require regulatory variations, supporting documentation and coordinated implementation across multiple markets.

The same principle applies to medical devices, where manufacturing process updates, supplier changes, component modifications and software improvements frequently require regulatory assessment before commercial implementation.

3. Commercial Growth Often Creates New Regulatory Obligations

Regulatory work is not driven solely by compliance activities.

Commercial teams continually seek opportunities to strengthen market competitiveness by expanding product claims, refreshing packaging, introducing new formulations, launching additional product variants or improving consumer appeal.

For health supplements and cosmetics, formulation improvements and marketing claims are particularly common as companies respond to changing consumer expectations. While these initiatives may appear commercially straightforward, they frequently require reformulation reviews, label assessment, product re-notification or entirely new regulatory submissions.

Similarly, pharmaceutical companies may expand indications following new clinical evidence, while medical device manufacturers may introduce additional models, accessories or upgraded configurations.

What appears to be a simple marketing decision often carries significant regulatory implications.

4. Supply Chains Continue to Evolve

Today’s global supply chain is constantly changing.

Companies increasingly introduce secondary manufacturing sites, appoint contract manufacturers, qualify alternative API suppliers, outsource packaging operations or establish additional testing laboratories to improve business continuity and optimise operational costs.

Medical device manufacturers also regularly introduce new manufacturing sites, component suppliers, accessories or updated device models.

Although these changes are commercially driven, they frequently require regulatory assessment and approval before implementation.

A well-managed supply chain therefore depends not only on procurement and operations, but also on effective regulatory planning.

The Hidden Challenge: Competing Priorities

In many organisations, post-approval regulatory activities compete with day-to-day commercial priorities.

Internal regulatory teams are expected to support new product launches, maintain existing licences, respond to headquarters, prepare variation submissions, review packaging artwork, answer distributor enquiries and monitor evolving regulatory requirements—all while ensuring uninterrupted product supply.

The result is often delayed submissions, inconsistent implementation timelines, prolonged coexistence of old and new packaging, delayed market launches and unnecessary commercial pressure.

These challenges rarely arise because teams lack capability.

They arise because lifecycle management requires continuous planning.

Regulatory Planning Creates Commercial Value

Companies that proactively plan their regulatory lifecycle are better positioned to coordinate:

• Regulatory variations
• Safety updates
• Packaging implementation
• Supplier and manufacturing changes
• Product renewals
• Commercial inventory management
• Future product launches

Regulatory planning is no longer an administrative activity—it has become an essential business function that supports commercial continuity while protecting regulatory compliance.

Need ongoing regulatory support instead of one-off projects?

Our Advanced Regulatory Support Plan provides continuous regulatory oversight to help companies manage post-approval changes, lifecycle maintenance and regulatory planning in Singapore.

How TRC Supports Long-Term Regulatory Success

At The Reg Consultants (TRC), we believe regulatory support should not begin only when a problem arises.

Our Regulatory Subscription Plans were developed specifically for companies requiring continuous regulatory support throughout the product lifecycle rather than one-off regulatory submissions.

By working alongside your internal regulatory, quality, manufacturing and commercial teams, we help companies anticipate regulatory changes, coordinate implementation strategies and maintain compliance while allowing internal teams to focus on business growth.

Product approval is only the beginning.

The companies that continue to succeed are those that plan beyond approval and invest in long-term regulatory lifecycle management.

If your organisation is looking for a proactive regulatory partner to support your post-approval activities in Singapore, we would be pleased to discuss how our Regulatory Subscription Plans can support your long-term business objectives.

 

 

我们偶尔会接到一些很特别的咨询。客户手里的产品，很难直接套进一个标准的注册路径里。

它们不完全是全新的化学实体（NCE）或生物制品。也不是简单直接的仿制药。但它们又不太可能仅凭文献论证就走通一条路。

这些产品常常“卡在中间”，需要仔细评估，才能理出合适的法规策略。

哪些产品会面临这种情况？

过去几年，我们见过不少这类咨询：

• 针对特定疾病人群的特殊营养产品

• 主要靠已发表文献和长期临床使用经验来支持的产品

• 含有成熟活性成分、已在国际上广泛使用多年的产品

• 在海外已获批但从未在新加坡注册过的产品

• 已知活性成分的新复方，且不属于处方药范畴

• 在不同国家被归为不同类别的产品

在这些情况下，我们发现企业常常有几个误区。

常见误区

“这个产品已经在国外获批了，所以在新加坡也应该按同样的路径走。”

不一定。海外批准可以作为参考，但新加坡的法规要求是独立的，本地的监管期望还是得满足。

“原产国怎么分类，新加坡就怎么分类。”

不同国家对同一个产品的分类可能完全不一样。一个产品在别国被归为非处方药、保健品、医学食品甚至医疗器械，在新加坡可能完全不同。这就是为什么在投入大量资源准备文件前，先做分类评估很重要。

“必须要做新的临床试验。”

不一定。根据产品、适应症和现有证据的情况，已发表文献、公认的临床使用经验、海外的监管经验以及现有临床数据，都可能派上用场。但到底够不够，得一个一个产品具体看。

“现有文献能自动支持任何新适应症。”

光有文献可能不够。文献的质量、相关性、适用性和一致性，都是决定能不能支撑拟用适应症的关键因素。

NDA-2路径的真实要求

就算一个产品可能走NDA-2路径，也别以为监管要求会宽松很多。该交的东西一样不少：模块一的行政文件、模块二的综述和概述、模块三的质量信息，以及支持安全性和有效性的临床证据。

关键区别不在于“不需要证据”，而在于证据包怎么构建、怎么论证。对于成熟活性成分、临床用途已经被广泛认可的产品，用已发表文献和现有数据做科学讨论，可能就不用再做新的临床研究。但每个产品都得独立评估，没办法一概而论。

为什么早期评估很重要

根据我们的经验，项目一开始最有用的，就是先搞清楚产品分类对不对、现有证据包够不够支撑预期的法规策略。这通常涉及：产品分类评估、法规路径评价、临床证据差距分析、标签审查、海外监管状态评估，以及在准备文件前先把潜在问题找出来。

早期评估往往能帮企业避免不必要的法规延误，也能在投入大量资源之前，把数据要求搞清楚。

TRC如何提供支持

TRC帮公司评估产品分类、评价法规路径、审查证据包，在启动申报计划前找出文件中的差距。如果你手里的产品不太符合常规注册类别，早期的法规评估通常能帮你理清：NDA-2这条路能不能走，以及需要哪些支持文件才过得去。

One of the more interesting enquiries we occasionally receive involves products that do not fit neatly into a conventional registration pathway.

They are not entirely new chemical entities or biological products.

They are not straightforward generic medicines.

Yet they may not be suitable for a simple literature-based justification alone.

These products often sit somewhere in between and require careful assessment before an appropriate regulatory strategy can be established.

Over the years, we have encountered enquiries involving:

• Specialised nutritional products intended for disease-specific patient populations
• Products supported primarily by published literature and established clinical use
• Products containing well-established active ingredients with extensive post-marketing experience internationally
• Products approved overseas but not previously registered in Singapore
• New combinations of known active ingredients which are not prescription products
• Products that are classified differently across jurisdictions

In many of these situations, there are often misconceptions regarding the regulatory pathway.

Common Misconceptions

“The product is already approved overseas, therefore the same regulatory approach should apply in Singapore.”

Not necessarily.

While overseas approvals can provide valuable supporting information, Singapore regulatory requirements remain independent and local expectations must still be addressed.

“The product classification in the country of origin will be the same in Singapore.”

Product classification can differ significantly between jurisdictions. A product classified as a non-prescription medicine, health supplement, medical food, or even a medical device elsewhere may be classified differently in Singapore.

This is one of the reasons why an early classification assessment is often important before substantial resources are invested in dossier preparation.

“A new clinical trial is always required.”

Not always.

Depending on the product, indication, and available evidence package, published literature, established clinical use, overseas regulatory experience, and existing clinical data may contribute to the overall justification strategy.

However, the adequacy of the evidence package must be assessed on a case-by-case basis.

“Existing literature can automatically support any new indication.”

The existence of published literature alone may not be sufficient.

The quality, relevance, applicability, and consistency of the available evidence remain important considerations when determining whether the proposed indication can be adequately supported.

Understanding the Regulatory Requirements

Even where a product may potentially be considered under an NDA-2 pathway, companies should not assume that regulatory expectations are significantly reduced.

The submission may still require a comprehensive dossier package including:

• Module 1 administrative documentation
• Module 2 summaries and overviews
• Module 3 quality information
• Clinical evidence supporting safety and efficacy

The key difference is often not the absence of evidence requirements, but rather how the evidence package is constructed and justified.

For products with well-established active ingredients and recognised clinical use, scientific discussion supported by published literature and existing evidence may reduce the need for generating entirely new clinical studies. However, each product must be assessed individually.

Why Early Assessment Matters

In our experience, one of the most valuable activities at the beginning of a project is determining whether the product is appropriately classified and whether the available evidence package is sufficient to support the intended regulatory strategy.

This may involve:

• Product classification assessment
• Regulatory pathway evaluation
• Clinical evidence gap analysis
• Labelling review
• Assessment of overseas regulatory status
• Identification of potential deficiencies prior to dossier preparation

An early assessment often helps companies avoid unnecessary regulatory delays and better understand the data requirements before committing significant development resources.

How TRC Can Support

At TRC, we assist companies in assessing product classification, evaluating regulatory pathways, reviewing evidence packages, and identifying potential dossier gaps before submission planning begins.

For products that do not fit neatly into conventional registration categories, an early regulatory assessment can often provide greater clarity on whether an NDA-2 strategy may be appropriate and what supporting documentation may be required to support a successful submission.

没有什么比拥有一套整理完善、及时更新的产品注册档案更让法规人感到踏实了。

但现实往往不是这样。

我们接手过太多“循环再利用”的旧档案——经历了多年的生命周期变更、多次上市后修订、生产场地更新、供应商更替和法规要求的演变，信息逐渐碎片化，历史模块长期未更新，最终档案已无法真实反映产品当前的生产和质量状态。

在启动任何新申请或市场扩张之前，我们常常不得不先投入大量精力进行深度差距分析，将档案与产品现状重新对齐。这不可避免地拖延了整体进度，增加了审评问询的轮次，也制造了不必要的法规工作量。

对于总部的档案管理团队来说，这种状况是可以理解的。他们要同时应对新供应商引入、分析方法更新、生产工艺改进、法规要求变化、上市后承诺履行、安全性更新以及跨多个管辖区的持续变更。在众多优先事项的挤压下，档案维护很容易从主动管理变成被动应对。

TRC的团队常帮助公司进行针对性的生命周期档案审查，在法规提交、合作伙伴尽职调查或市场扩展活动之前，提前识别需要对齐的关键领域。

生命周期档案维护中的常见审查要点

模块一 — 行政与法规文件

行政文件应保持更新且随时可提交。

常见问题包括：授权信和声明函已过期、最新版说明书或包装图稿未替换嵌入档案、GMP证书未标注有效期或已失效、生产场地信息在各模块中不一致、原辅料授权文件和CEP未及时维护。

这些看似细小的行政问题，在审评过程中往往会造成不必要的沟通和澄清延误。

模块二 — 档案整体一致性

模块二通常是快速判断档案质量的最佳窗口。

质量综述、非临床综述和临床综述需要与模块三、四、五中的最新信息保持一致。我们常遇到的状况包括：生产描述已过时、质量标准与模块三不符、稳定性结论陈旧、临床定位已不再适用现有适应症、生命周期变更未完整整合。

维护良好的模块二能显著提升档案的可读性，减少下游的审评问询。

模块三 — 质量与生产工艺的生命周期管理

对于成熟药品而言，模块三通常是生命周期管理中最操作密集的领域。

关键审查要点包括：生产方角色与职责是否反映当前技术协议、是否引入了新的外包检测或生产场地、工艺验证报告是否更新、是否实施了新的分析控制及验证程序、年度稳定性承诺及持续稳定性数据是否已纳入、质量标准是否与现行方法对齐、批配方与拟议商业批量的匹配情况、药剂开发部分是否仍反映当前实践、现行批分析数据及杂质控制策略。

在许多老旧档案中，药剂开发部分往往是历史性描述，长期未根据实际工艺演变进行更新。

不同产品类型的生命周期考量

仿制药与成熟产品
对于成熟仿制药组合，生命周期管理更多是确保所有已实施的变更已完整反映在档案中。涉及生产工艺更新、质量标准修订、供应商变更、分析方法改进、稳定性周期延长、包装更新等，需要进行定期档案梳理以维持信息一致。

新化学实体（NCE）
对于NCE产品，生命周期维护不仅限于常规变更管理。法规团队还需评估临床定位演变、新增适应症、新剂量规格或剂型、风险管理活动更新及全球法规对齐策略。

生物类似药
生物类似药的生命周期管理更为复杂，因为在整个产品生命周期中，可比性始终是重点。即便是相对较小的生产变更，也可能需要审慎评估以确保与参照药的可比性论证持续成立。

细胞与基因治疗产品
对于ATMPs、细胞治疗和基因治疗产品，生命周期管理涉及高度动态的运营和法规环境。需持续关注起始物料控制策略、载体及病毒安全性更新、效价检测方法演变、冷链及物流确认，以及各区域快速变化的法规期望。

模块四 — 非临床生命周期更新

模块四在许多成熟产品中相对稳定，但以下情况下仍可能需要更新：新杂质产生、修订的毒理学评估报告、新增辅料安全性考量、额外的非临床论证数据。

模块五 — 临床及药物警戒维护

模块五的生命周期维护可能涉及：新增临床研究报告、适应症扩展支持、更新的文献综述、PSUR/PBRER维护、风险管理计划更新、以及与上市后安全性观察及承诺的持续对齐。

eCTD生命周期维护

对于采用eCTD格式维护的产品，定期技术性清理同样重要，包括超链接验证、书签完整性检查、生命周期操作准确性、序列一致性及区域结构对齐。技术层面的不一致可能在审评过程中造成可避免的审查障碍。

支持可持续的法规生命周期管理

档案维护或许操作繁琐，尤其对于跨多个市场管理的成熟产品组合。但前瞻性的生命周期管理能显著减少法规差距，提升提交准备度，并在合作伙伴尽职调查和市场扩展活动中更加从容。

TRC理解成熟药品、生物制品、生物类似药及先进治疗产品在生命周期档案维护中的复杂性。我们的法规生命周期管理支持服务，旨在帮助公司识别档案差距、梳理历史文件，并在产品持续全球演进的过程中，始终保持提交准备度。

There is no better feeling than having an organised and updated product dossier within a regulatory inventory.

Regulatory professionals will resonate with this immediately.

In reality, many companies eventually encounter what we often refer to as “recycled dossiers” — dossiers which have undergone years of lifecycle changes, manufacturing updates, process improvements, supplier transitions, and post-approval variations across multiple markets. Over time, information becomes fragmented, historical sections remain outdated, and internal documentation no longer fully reflects current operational practice.

Before any new submission or market expansion can proceed, significant gap assessments may be required to reconcile the dossier with the current state of the product.

This ultimately delays timelines, increases deficiency queries, and creates additional regulatory workload.

For central dossier management teams, this situation is understandable. Regulatory lifecycle management is complex. Teams are simultaneously managing:

• new suppliers,
• updated analytical methodologies,
• manufacturing process improvements,
• changing regulatory expectations,
• post-marketing commitments,
• safety updates,
• and ongoing variation implementation across multiple jurisdictions.

With competing priorities, dossier maintenance can gradually become reactive rather than proactive.

At TRC, we often support companies by performing targeted lifecycle dossier reviews to identify critical areas requiring alignment before regulatory submission, partner due diligence review, or market expansion activities.

Key Areas Commonly Reviewed During Lifecycle Dossier Maintenance

Module 1 — Administrative and Regulatory Documentation

Administrative documentation should remain current and submission-ready.

Common areas requiring verification include:

• validity of Letters of Authorisation and declaration letters,
• latest approved SmPC, PI, IFU, and packaging artwork,
• validity of GMP certificates and manufacturing licences,
• alignment of manufacturing site information across modules,
• maintenance of Drug Master Files and CEP documentation,
• regional administrative consistency.

In many mature dossiers, outdated administrative documents remain embedded within historical submission packages, creating unnecessary clarification rounds during review.

Module 2 — Overall Dossier Consistency

Module 2 often provides the fastest indication of the overall quality and maintenance status of a dossier.

Quality Overall Summaries, Nonclinical Overviews, and Clinical Overviews should remain aligned with the latest information presented in Modules 3, 4, and 5.

Common issues observed include:

• outdated manufacturing descriptions,
• specifications inconsistent with Module 3,
• obsolete stability conclusions,
• historical clinical positioning no longer aligned with current indications,
• incomplete integration of lifecycle changes.

A well-maintained Module 2 significantly improves dossier readability and reduces downstream regulatory queries.

Module 3 — Quality and Manufacturing Lifecycle Management

For mature pharmaceutical products, Module 3 maintenance becomes one of the most operationally intensive areas of lifecycle management.

Critical review areas may include:

• manufacturing roles and responsibilities reflecting current technical agreements,
• newly introduced outsourced testing or manufacturing sites,
• updated process validation reports,
• implementation of new analytical controls and validation procedures,
• annual stability commitments and ongoing stability data updates,
• alignment of specifications with current methodologies,
• consistency between batch formulae and proposed commercial batch sizes,
• continued validity of pharmaceutical development sections,
• current batch analysis data and impurity control strategies.

In many legacy dossiers, pharmaceutical development sections are historically written and no longer adequately reflect internal process evolution implemented over time.

Product-Specific Lifecycle Considerations

Generic and Mature Products

For mature generic portfolios, lifecycle management frequently involves ensuring that all implemented variations are consistently reflected throughout the dossier.

Over time, multiple post-approval changes may have been introduced involving:

• manufacturing process updates,
• specification revisions,
• supplier changes,
• analytical method improvements,
• stability extensions,
• packaging updates.

Without periodic dossier restructuring, inconsistencies may emerge between approved changes and the current dossier state maintained internally.

New Chemical Entities (NCEs)

For NCE products, lifecycle maintenance often extends beyond routine variation implementation.

Regulatory teams may need to evaluate:

• evolving clinical positioning,
• additional indications,
• new dosage strengths or formulations,
• updated risk management activities,
• global regulatory alignment strategies,
• incorporation of new post-marketing commitments.

As global development programmes mature, maintaining consistency across regional dossiers becomes increasingly important for efficient lifecycle expansion.

Biosimilars

Biosimilar lifecycle management introduces additional complexity due to the continued importance of comparability throughout the product lifecycle.

Common lifecycle review considerations may include:

• manufacturing process evolution,
• comparability exercise updates,
• analytical similarity reassessment,
• control strategy refinement,
• evolving reference product considerations,
• post-approval process optimisation,
• alignment between manufacturing changes and regulatory commitments across markets.

Even relatively small manufacturing changes may require careful assessment to ensure continued demonstration of biosimilarity.

Cell and Gene Therapy Products

For advanced therapy medicinal products (ATMPs), cell therapies, and gene therapy products, lifecycle management may involve highly dynamic operational and regulatory environments.

Areas commonly requiring ongoing review include:

• chain of identity and chain of custody documentation,
• starting material control strategies,
• vector and viral safety updates,
• evolving potency methodologies,
• comparability following manufacturing changes,
• long-term follow-up commitments,
• cold chain and logistics qualification,
• rapidly evolving regulatory expectations across regions.

Given the complexity of these products, maintaining an organised and continuously updated dossier structure becomes critical for sustainable lifecycle management.

Module 4 — Nonclinical Lifecycle Updates

While Module 4 may remain relatively stable for many mature products, updates may still be required where:

• new impurities emerge,
• revised toxicological assessments become available,
• new excipient safety considerations arise,
• additional nonclinical justification data is generated.

Module 5 — Clinical and Pharmacovigilance Maintenance

Lifecycle maintenance within Module 5 may involve:

• inclusion of new Clinical Study Reports (CSRs),
• support for indication expansion,
• incorporation of updated literature reviews,
• PSUR/PBRER maintenance,
• Risk Management Plan (RMP) updates,
• alignment with post-marketing safety observations and commitments.

As products mature commercially, pharmacovigilance activities often become increasingly important in supporting continued regulatory confidence.

eCTD Lifecycle Maintenance

For products maintained in eCTD format, periodic technical housekeeping is equally important.

This may include:

• hyperlink verification,
• bookmark integrity checks,
• lifecycle operator accuracy,
• sequence consistency,
• regional structure alignment.

Technical inconsistencies within eCTD submissions can create avoidable review complications during regulatory assessment.

Supporting Sustainable Regulatory Lifecycle Management

Dossier maintenance may be operationally demanding, particularly for mature portfolios managed across multiple markets. However, proactive lifecycle housekeeping significantly reduces regulatory gaps, improves submission readiness, and facilitates smoother partner due diligence and market expansion activities.

At TRC, we understand that lifecycle management is not a one-time exercise. As products continue to evolve commercially and technically, regulatory dossiers must continuously adapt alongside manufacturing updates, post-approval variations, safety commitments, analytical improvements, and changing regulatory expectations across different regions.

This becomes especially relevant for companies managing mature pharmaceutical products, biosimilars, advanced therapy products, or multi-market portfolios where internal regulatory resources are often balancing multiple competing priorities simultaneously.

Our regulatory lifecycle management support services are designed to assist companies in:

• identifying dossier gaps,
• restructuring historical documentation,
• reviewing lifecycle implementation consistency,
• maintaining submission readiness,
• and supporting ongoing regulatory maintenance activities as products continue to evolve globally.

For companies requiring longer-term operational support, TRC also offers flexible regulatory subscription support models tailored to ongoing dossier maintenance, lifecycle management activities, variation support, and regional regulatory coordination needs.

Good dossier practice may often go unnoticed internally — until the next submission, partner review, or market expansion opportunity arrives. Maintaining an organised and continuously aligned dossier today can significantly reduce regulatory burden tomorrow.

随着药物研发日益艰难、临床周期拉长、法规门槛不断抬高，越来越多的制药公司和新兴电商品牌开始将目光转向保健品和化妆品。与此同时，消费者对预防性健康、日常保健和功能性产品的关注度也在持续上升。多年前我们就看到“超级食品”和保健成分的兴起，但今天的市场竞争已远非当年可比。

随着竞争加剧，许多公司为了让产品脱颖而出，开始将配方和定位做得越来越像“药”。

这正是法规风险开始浮现的地方。

一、先搞清楚你在做什么产品

产品开发的第一步，是想清楚你究竟在创造一个什么类别的产品。简单来说：

保健品，是由维生素、矿物质、氨基酸、传统成分或植物提取物制成的产品，用于补充日常膳食、支持身体功能。

化妆品，是主要用于清洁、美化、赋香、保护或改善皮肤、头发或身体外观的产品。

这些定义看起来不难，但真正的法规风险，往往来自产品如何被配方、如何被定位、如何被推向市场。

二、三个核心：配方、标签、宣称

很多情况下，产品的法规风险并非来自某一个成分，而是来自产品的整体呈现。

1. 配方

在设计配方时，企业需要理解每个成分在生理上的作用，以及组合后的配方是否真正支撑产品的预期用途。我们看到越来越多的公司，将多种植物提取物、维生素、传统草药、功能性食品成分和新型原料体系，糅合成极其复杂的配方，试图让产品看起来更有“功效”。

在某些情况下，整体配方可能已悄然滑向边界地带，甚至趋近于治疗性定位。新型剂型和递送系统（如脂质体技术）也可能因产品定位和宣称的需要，面临额外的法规考量。

2. 产品标签与定位

产品标签，应当与产品类别和消费者对产品的认知保持一致。需要仔细考量的方面包括：产品的预期用途、使用说明、剂量建议、目标消费人群，以及整体的市场营销呈现。有些时候，即便配方本身没有明显问题，产品的整体呈现和营销方向，也可能开始制造出一种“药”的印象。

3. 宣称

这是产品审评中最常见的问题之一：宣称超出了产品应有的类别范围。例如：

• 化妆品宣称能舒缓湿疹或牛皮癣

• 护发精华或保健品声称能刺激头发再生、逆转脱发

• 含咖啡因或草本兴奋剂的能量补充剂，声称能治疗慢性疲劳或改善倦怠症状

• 保健品声称能逆转骨关节炎、自然控制糖尿病或预防心血管疾病

• 产品虽定位为化妆品或保健品，却暗示具有疾病预防、治疗效果或医疗成效

许多企业认为，增加更多的营销宣称，能让产品在商业上显得更强。但过度或缺乏支撑的宣称，反而可能引发更多的法规关注。更可持续的做法，是聚焦在少数几条有充分支撑的宣称上，以公认参考文献、已发表文献或成熟的成分数据作为依据。

三、我们经常看到的误区

最常见的误区之一，是以为在别的国家能被接受的产品，在新加坡的法规框架下就能自动放行。

事实未必如此。

例如，某些在海外作为保健品销售的新兴保健成分或产品类别——如含有SARMs的补充剂、定位为认知增强的新型蘑菇提取物、促睾补充剂、CBD类保健产品、肽类美容补充剂——在新加坡可能需要更审慎的法规评估，取决于成分特性、剂量强度、预期用途和产品宣称。

还有一些产品，标签上虽然没有直接提及疾病，但整体的广告和营销物料却在强烈暗示治疗意图。例如：

• 祛痘精华宣称“临床验证祛痘治疗”

• 护发产品声称能“刺激头发再生”

• 能量补充剂声称能“支持身体压力恢复”

• 保健品暗示能控制糖尿病、关节炎、激素失调或其他疾病

就在这个环节，企业在无意中将自己的产品推入了边界地带，触发了额外的法规审查或分类争议。

四、进入市场前，先问自己几个关键问题

在进口或上市之前，企业应当认真思考：

• 配方在逻辑上是否支撑产品的预期用途？

• 宣称是否适度，且有科学支撑？

• 产品的整体呈现，是否在向药品靠拢？

• 新型成分或技术，在目标产品类别中是否可被接受？

• 相比其他市场，新加坡的法规是否会以不同的方式解读这个产品？

及早评估这些方面，能帮你避免后期不必要的配方重做、营销修改和注册延误。

五、为什么法规定位要趁早？

很多公司直到产品配方、品牌和营销概念全部敲定，才开始考虑法规要求。

但到了这个阶段，如果产品定位已经过于趋近治疗性，往往需要大幅调整。这种情况在以下产品中尤为常见：主打强效定位的产品、运用新型原料技术的产品、高浓度植物复方产品，以及试图打造更具“临床效果感”的药妆概念产品。

在实操层面，法规评估不应只看某个成分是否“可以用”，更要看产品的整体呈现、配方逻辑和预期宣称，是否始终与产品类别保持一致。这也是为什么在批量生产、包装定稿和营销铺开之前，尽早展开法规策略讨论如此重要。

六、TRC如何提供支持

TRC为企业面向新加坡市场的保健品、化妆品及边界产品，提供早期法规评估服务。

支持范围包括：产品分类评估、配方与成分审阅、宣称与标签评估、边界风险识别，以及在进口或递交申请前，就市场定位给出合规指引。

很多情况下，一次早期的法规审阅，就足以在大量时间和资源被投入上市活动之前，识别出潜在问题。

如果你正在评估一款新的保健品、化妆品或功能性保健产品是否适合进入新加坡市场，欢迎联系TRC进行初步探讨。

With increasing challenges surrounding drug development, long clinical timelines and rising regulatory barriers, many pharmaceutical companies and emerging e-commerce brands are beginning to expand into health supplements and cosmetics.

At the same time, consumers are becoming increasingly focused on preventive health, wellness and functional products that support daily wellbeing. We started seeing this trend years ago with the rise of “superfoods” and wellness-focused ingredients, but the market today has become much more competitive.

As competition increases, many companies are now trying to formulate and position their products to look increasingly “drug-like” in order to stand out in the market.

This is where regulatory concerns may start to arise.

Understanding the Intended Product Category

One of the first steps during product development is understanding what type of product you are actually trying to create.

Simply:

Health Supplements

Health supplements are products made from vitamins, minerals, amino acids, traditional ingredients or botanical extracts intended to supplement the diet and support healthy body functions.

Cosmetics

Cosmetics are products intended primarily for cleansing, beautifying, perfuming, protecting or improving the appearance of the skin, hair or body.

While these definitions may appear straightforward, the actual regulatory concerns often arise from how the product is formulated, positioned and marketed.

The Three Core Areas: Formulation, Label and Claims

In many situations, the regulatory risk of a product does not come from a single ingredient alone, but from the overall presentation of the product.

1.Formulation

When designing a formulation, companies should understand how the individual ingredients work physiologically and whether the combined blend supports the intended purpose of the product.

We increasingly observe companies combining:

• multiple botanical extracts,
• vitamins,
• traditional herbal ingredients,
• functional food extracts,
• and novel ingredient systems

into highly complex blends designed to appear more “efficacious”.

In some situations, the overall formulation may begin moving closer towards a borderline or therapeutic positioning.

Novel dosage forms and delivery systems such as liposomal technologies may also require additional consideration depending on the product positioning and intended claims.

2.Product Label and Positioning

The product label should align with the intended product category and consumer understanding of the product.

Areas that should be considered include:

• intended purpose of the product,
• directions for use,
• dosage recommendations,
• target consumers,
• and overall marketing presentation.

In some situations, even where the formulation itself appears acceptable, the overall presentation and marketing direction may begin creating a therapeutic impression.

3. Claims

One of the most common issues observed during product review is the use of claims that extend beyond the intended product category.

Examples may include:

• cosmetics claiming to relieve eczema or psoriasis,
• hair serums or supplements claiming to stimulate hair regrowth or reverse hair loss,
• energy supplements containing caffeine or herbal stimulants claiming to treat chronic fatigue or improve burnout symptoms,
• supplements claiming to reverse osteoarthritis, control diabetes naturally, or prevent cardiovascular disease,
• or products implying disease prevention, therapeutic benefit, or medical treatment outcomes despite being positioned as cosmetics or health supplements.

In many situations, companies assume that adding more marketing claims makes the product appear stronger commercially. However, excessive or unsupported claims may instead increase regulatory concerns.

A more sustainable approach is to focus on a smaller number of well-supported claims supported by recognised references, published literature or established ingredient data.

Common Misconceptions We Commonly Observe

One of the more common misconceptions is assuming that a product accepted in another country will automatically be acceptable under Singapore’s regulatory framework.

This may not always be the case.

For example, certain novel wellness ingredients or emerging product categories marketed overseas — such as SARMs-containing supplements, novel mushroom extracts positioned for cognitive enhancement, testosterone-boosting supplements, CBD-type wellness products, or peptide-based beauty supplements — may require closer regulatory consideration in Singapore depending on:

• ingredient profile,
• dosage strength,
• intended purpose, and
• product claims.

Similarly, some products may technically avoid directly mentioning diseases on the label, while the overall advertising and marketing materials strongly imply therapeutic intent.

Examples may include:

• acne serums marketed as “clinically proven acne treatment”,
• hair products claiming to “stimulate hair regrowth”,
• energy supplements claiming to “support body stress recovery ”,
• or supplements implying management of diabetes, arthritis, hormonal imbalance, or other medical conditions.

This is where companies may unintentionally move their product into a borderline category and trigger additional regulatory scrutiny or classification concerns.

Key Questions to Consider Before Market Entry

Before importing or launching a product, companies should consider:

• Does the formulation logically support the intended product purpose?
• Are the claims proportionate and scientifically supportable?
• Does the overall product presentation resemble a therapeutic product?
• Are novel ingredients or technologies acceptable within the intended category?
• Could the product potentially be interpreted differently under Singapore regulations compared to other markets?

Early assessment of these areas can help reduce unnecessary reformulation work, marketing revisions and regulatory delays later in the process.

Why Early Regulatory Positioning Matters

In many situations, companies only begin considering regulatory requirements after the product formulation, branding and marketing concepts have already been finalized.

However, by that stage, significant changes may already be required if the product positioning begins leaning too closely towards therapeutic territory.

This is particularly common in products developed around:

• aggressive efficacy positioning,
• novel ingredient technologies,
• highly concentrated botanical blends,
• or “cosmeceutical”-style concepts designed to appear more clinically effective.

In practice, regulatory assessment should not only focus on whether an ingredient is “allowed” individually, but also whether the overall product presentation, formulation rationale and intended claims remain consistent with the intended product category.

This is one of the reasons why early regulatory strategy discussions are important before large-scale manufacturing, packaging finalisation or marketing rollout begins.

How TRC Can Support

TRC supports companies with early-stage regulatory assessment for health supplements, cosmetics and borderline products intended for the Singapore market.

Support may include:

• product classification assessment,
• formulation and ingredient review,
• claims and label evaluation,
• identification of borderline regulatory risks,
• and guidance on appropriate market positioning before importation or submission activities.

In many situations, an early regulatory review is often sufficient to identify potential issues before significant time and resources are invested into product launch activities.

If your company is currently evaluating a new supplement, cosmetic or functional wellness product for the Singapore market, feel free to contact TRC for an initial discussion.

In January 2026, HSA introduced a new pathway for certain generic drugs that have been used in Singapore’s clinical settings for years but do not have a corresponding registered reference product in Singapore.

For overseas companies holding mature generic portfolios or essential medicines, this may potentially create new opportunities to evaluate Singapore market entry possibilities which may not have been considered previously.

This is not a shortcut registration pathway and HSA’s quality, safety and efficacy expectations would still apply. However, from a regulatory strategy perspective, the pathway may remove one of the key barriers which historically prevented some overseas generic products from being considered for registration in Singapore.

What Products May Qualify?

Under HSA’s guidance, several key criteria would generally need to be fulfilled.

Well-established safety and efficacy

The product should demonstrate established safety and efficacy supported by recognised references and pharmacopoeial standards. This pathway is intended for medicines with long-standing clinical use rather than innovative or newly developed products.

Documented clinical use in Singapore

The active ingredient, dosage form and strength should either be listed on the Ministry of Health (MOH) Standard Drug List (SDL) or have been included on a public healthcare institution’s Pharmacy & Therapeutics (P&T) list for at least five years prior to submission.

No corresponding Singapore reference product

Products with an existing corresponding Singapore reference product would generally not qualify under this pathway, as the standard generic registration route would remain applicable.

For companies exploring the standard registration route for generics in Singapore, you may also wish to read our article on Generic Drug Application requirements and common regulatory considerations in Singapore.

In addition, HSA would also expect the product to demonstrate acceptable quality standards, overseas regulatory history and no known significant global safety concerns.

The Expression of Interest (EOI) Comes First

Before submitting a full Generic Drug Application (GDA), applicants are required to submit an Expression of Interest (EOI) to HSA at least three months before the intended submission date.

The EOI should clearly justify the product’s eligibility under the pathway together with its local clinical relevance and supporting product background.

From a practical perspective, this step is important as HSA would first assess whether the product is suitable to proceed under the pathway before the formal submission is made.

Why This May Matter for Overseas Generic Companies

From experience, one of the common assumptions among overseas generic companies is that products without a corresponding Singapore reference product are generally not suitable for registration locally.

As a result, some mature generic portfolios may never have been assessed for Singapore registration opportunities despite having established overseas use and supporting clinical history.

This pathway may therefore be relevant for companies holding:

• Mature generic medicines with long-standing overseas market history;
• Essential medicines supplied to hospital settings;
• Products already used within public healthcare systems overseas;
• Generic portfolios intended for ASEAN market expansion.

However, one of the common challenges is that many dossiers were originally prepared for other markets and may not fully align with Singapore regulatory expectations from the beginning.

In practice, companies may still need to assess:

• Whether the product genuinely fulfils the eligibility criteria;
• Availability of acceptable supporting literature and pharmacopoeial standards;
• Alignment of the dossier against HSA expectations;
• Whether additional bridging or bioequivalence justification may still be required;
• Suitability of the proposed indication and product positioning.

The key issue is often not simply whether the product may potentially fit the pathway, but whether the available supporting package is sufficiently aligned with HSA’s expectations before submission planning starts.

How TRC Can Support

TRC supports overseas pharmaceutical companies with Singapore regulatory strategy, product registration and lifecycle management activities. For companies exploring whether their products may potentially fit this pathway, TRC can support with early product assessment, regulatory gap review, EOI preparation and overall submission planning based on the product profile and available supporting data.

In many situations, an initial assessment is usually sufficient to determine whether the pathway may realistically be feasible and what areas may require further preparation before proceeding with submission activities.

If your company is currently evaluating Singapore market entry opportunities for mature generic or essential medicine portfolios, feel free to contact TRC for an initial discussion.

近年来，越来越多中国中小型企业开始关注“出海”，而新加坡凭借其稳定的商业环境及相对清晰的监管体系，成为不少企业进入东南亚市场的首选。

在实际接触中，我们也发现，许多企业在尚未完全厘清自身目标的情况下，便开始推进市场进入，或委托第三方提供“一站式服务”。
虽然这种方式看似高效，但若前期关键问题未考虑清楚，往往会在后期运营或扩展过程中带来不必要的成本与调整。

在进入新加坡市场前，企业可以先思考以下五个问题：

1. “出海”对你来说意味着什么？

企业需要先明确自身目标：

• 是将新加坡作为进入东南亚市场的“踏板”？
• 还是作为试水市场？
• 又或是基于长期布局或个人规划？

不同目标将直接影响产品选择及进入策略。
例如，若以区域拓展为目标，建议优先选择最具竞争力的产品进行评估；若为试水，则需更谨慎评估整体成本与风险。

2. 你是否真正了解目标市场？

在实际操作中，不少企业依赖第三方提供市场信息，但市场判断本身仍需企业自行把握。

企业应思考：

• 目标人群是谁？
• 产品是否具备真实需求？
• 是否具有竞争优势？

如条件允许，进行基础市场调研，将有助于形成更清晰的判断，而不是完全依赖外部信息。

3. 产品是否符合新加坡的监管要求？

不同产品在新加坡可能归类为不同监管类别，例如：

• 药品（Drug）
• 保健品（Health Supplements）
• 中成药（CPM）
• 医疗器械（Medical Device）
• 化妆品（Cosmetics）

不同类别对应不同的监管路径及数据要求，例如：

• 药品：是否能够接受生产场地检查？是否具备完整的质量、临床及安全数据？
• 保健品：标签及效用是否符合规定？
• 中成药：是否具备相关批准文件及检测报告？
• 医疗器械：技术文件是否符合国际标准？
• 化妆品：标签、效用及生产资质是否符备案报需求？

企业需要评估自身产品是否具备满足相应监管标准的能力，而不仅仅是“是否可以进入市场”。不同产品类别所涉及的具体监管要求差异较大，实际评估通常需要结合产品配方、用途及申报路径进行详细分析。

4. 你如何看待第三方（中间服务商）的参与？

在实际操作中，不少企业会将公司设立、产品合规及市场进入完全交由第三方处理。

在这种模式下，企业需要特别关注：

• 注册主体及相关资质的归属
• 企业是否掌握关键技术资料及合规文件
• 是否对单一服务商产生依赖

企业也需要特别关注注册主体及相关资质的归属问题。在部分模式下，产品注册或备案可能由第三方持有，这将直接影响企业对产品在当地市场的控制权及后续调整的灵活性。

同时，关键技术资料及合规文件是否由企业自身掌握，也会影响未来更换合作方或拓展其他市场时的效率与成本。

在实际项目中，我们也遇到企业在进入市场后，才发现自身并不掌握关键合规资料或注册控制权，从而在后续调整中产生额外时间及成本。不同模式各有其适用场景，关键在于企业是否在前期充分了解相关安排。

5. 你是否具备持续投入的资源与预算？

进入新加坡市场不仅是一次性的投入，还包括：

• 合规维护
• 本地运营
• 后续市场拓展

作为一个高成本市场，企业需要评估自身是否具备持续投入的能力，而不仅仅是完成初期进入。

当上述问题有了初步方向后，企业可以更清晰地判断适合自身的进入模式。

在实际项目中，我们通常会先了解企业的业务目标，再协助评估产品与法规之间的差距（Gap Analysis），并制定相应的合规路径，而不是直接进入执行阶段。

在适合的情况下，我们也可以结合项目需求，与本地或区域合作伙伴协作，在整体合规策略下提供沟通与协调支持，协助企业更顺利推进项目。

进入新加坡市场，不只是一个执行问题，而是一个涉及战略、合规及长期规划的决策。

相比“快速进入”，选择合适的路径，往往更为关键。

如果您正在评估进入新加坡市场，并希望在明确业务目标的基础上制定合规路径，欢迎与我们进一步交流。